A recent case series of five patients with severe asthma with chronic rhinosinusitis, nasal polyposis, and OSA found a remarkable reduction in OSA symptoms in all patients after 6 months of therapy with dupilumab, an IL-4 and IL-13 antagonist [54]. Here, IL13 is linked to obstructive sleep apnea syndrome.